- KYPROLIS® (carfilzomib) is indicated in combination with dexamethasone, or with lenalidomide plus dexamethasone, or with daratumumab plus dexamethasone, ... Read More Read Less
Power possibility for your patients
with deep and durable responses
4 carfilzomib (KYPROLIS®) combinations received
NCCN Category
1 Recommendations for treating
RRMM at first relapse and beyond.1
Learn about your peers’ experience treating RRMM patients with KYPROLIS®
Dr. Jennifer Caudle with Dr. Joseph Mikhael
“While the majority of patients with multiple myeloma receive an immunomodulatory agent, or IMiD, as part of their initial treatment, there’s been growing interest in what their next treatment should be if they don’t respond or become refractory to IMiDs. But with the approval of a regimen based on the CANDOR study results, these patients now have an IMiD-free option. What that regimen is, and the key findings that came out of the CANDOR study are what we’ll be focusing on today.”
with Ariel F. Grajales-Cruz, MD
An expert’s perspective on including KYPROLIS® at first relapse to help achieve depth and duration of remission.
“First relapse is a hard conversation …at any point things can change. In my practice, we tend to reach for the drugs that give us the deep and long remissions early.”
with Jeremy S. McDuffie, MD
Treatment considerations for various RRMM patient situations.
“We know that depth of remission generally correlates with time in remission. And depth and time provide tangible meaningful experiences to the patient.”
with M. Yair Levy, MD
A peer’s view on the value of KYPROLIS® dosing options within approved treatment combinations.
“In my practice, I use what I think will optimize outcomes in my patients.”
An expert’s perspective on including KYPROLIS® at first relapse to help achieve depth and duration of remission.
VIEW VIDEOTreatment Considerations for Various RRMM Patient Situations.
VIEW VIDEOA peer’s view on the value of KYPROLIS® dosing options within approved treatment combinations.
VIEW VIDEOIMiD = immunomodulatory imide drug; NCCN = National Comprehensive Cancer Network® (NCCN®); RRMM = relapsed or refractory multiple myeloma.
Please see accompanying full Prescribing Information.
Please see accompanying full Prescribing Information.
Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Multiple Myeloma V.3.2024. © National Comprehensive Cancer Network, Inc. 2024. All rights reserved. Accessed April 8, 2024. To view the most recent and complete version of the guideline, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.